|
Sample
|
% viability, RBL-2H3a
|
% inhibition of A23187-induced β-hexosaminidase releaseb
|
|---|
|
100 μM
|
500 μM
|
10 μM
|
100 μM
|
500 μM
|
|---|
|
β-amyrin acetate (1)
|
98.3 ± 2.9
|
c
|
0.3 ± 0.6
|
0.7 ± 1.2
|
c
|
|
scopoletin (4)
|
96.0 ± 4.0
|
93.7 ± 6.5
|
3.7 ± 4.7
|
13.7 ± 8.0
|
23.0 ± 8.0**d
|
|
β-sitosterol-3-O-β-D-glucoside (5)
|
96.0 ± 1.0
|
c
|
5.0 ± 5.6
|
7.7 ± 3.8
|
c
|
|
dihydrodehydrodiconiferyl alcohol 4-O-β-D-glucoside (6)
|
97.3 ± 2.5
|
e
|
7.0 ± 10.4
|
12.7 ± 7.6
|
e
|
|
dihydrodehydrodiconiferyl alcohol 9-O-β-D-glucoside (7)
|
97.7 ± 2.1
|
95.3 ± 4.2
|
3.3 ± 4.2
|
16.3 ± 5.5*
|
18.0 ± 8.7*
|
- A mixture of β-sitosterol (2) and stigmasterol (3) was toxic towards RBL-2H3 cells at the concentration of 200 μg/mL (73.7 ± 11.7% viability) and 100 μg/ml (78.7 ± 11.6% viability) and inactive at the concentration of 10 μg/mL (5.0% ± 5.0% inhibition) in A23187-induced degranulation assay
- aThe cytotoxicity of samples to RBL-2H3 was evaluated using MTT viability assay; results are presented as mean ± SD (n = 3)
- bDexamethasone (10 nM) was used as the positive control and inhibited 93.7 ± 1.5%** of A23187-induced β-hexosaminidase release in RBL-2H3 cells. Results are presented as mean ± SD (n = 3); *p < 0.05, **p < 0.001 compared with the control value (A23187 only)
- cPrecipitate was formed upon the addition into the medium at the concentration of 500 μM, therefore the result could not be justified
- dScopoletin (500 μM) exerted 30.0 ± 7.1% inhibition of antigen-induced β-hexosaminidase release (mean ± SD, n = 2)
- eDihydrodehydrodiconiferyl alcohol 4-O-β-D-glucoside was not tested at the concentration of 500 μM, however, it was nontoxic towards RBL-2H3 cells (96.0 ± 6.9% viability) and inactive in A23187-induced degranulation assay (10.0 ± 4.6% inhibition) at the concentration of 200 μM
